BURLINGTON, Mass.–(BUSINESS WIRE)–
Decision Resources, one of the world’s leading research and advisory
firms focusing on pharmaceutical and healthcare issues, finds that by
2020, the value of the market for bladder cancer therapies in the United
States and Europe will have increased dramatically due in part to the
arrival of emerging therapies that will carve out niche roles. The
current standard of care for non-muscle-invasive bladder cancer (NMIBC)
includes chemotherapy within the bladder and Bacillus Calmette-Guérin
(BCG) immunotherapy, which are associated with significant side effects.
Approximately 50 percent of patients either fail to respond to treatment
or suffer disease recurrence within ten years.
BCG dominates the NMIBC setting, and while none of the emerging
therapies will overcome BCG in treating NMIBC, they will be used as
alternatives to older chemotherapies, and in the instance of
Allergan/Spectrum Pharmaceuticals’ EOquin, as treatment in the immediate
postoperative setting within NMIBC. According to Bladder
Cancer, EOquin is expected to be the first novel agent to
launch for the treatment of bladder cancer, and the only one to launch
before 2015. Decision Resources forecasts that EOquin will be approved
for single immediate postoperative use in 2013 in the United States and
in 2014 in France, Germany, Italy, Spain and the United Kingdom.
Additionally, Decision Resources forecasts approval for multiple
instillations in 2017 in the United States, Germany and the United
Kingdom, and in 2018 in France, Italy and Spain. In addition to EOquin,
experts believe Celgene’s Abraxane will benefit NMIBC patients. Decision
Resources forecasts Abraxane will launch in the United States in 2018
for bladder cancer.
“Marketers of bladder cancer therapies will find that NMIBC is the most
lucrative setting because it encompasses about three-quarters of all
bladder cancer patients. Within the treatment algorithm for NMIBC, the
most feasible opportunity for novel therapies are the single immediate
postoperative instillation and multiple adjuvant instillations for low-
and intermediate-risk NMIBC,” said Analyst Mary Argent-Katwala, Ph.D.
“Unlike other tumor types—such as breast cancer, colorectal cancer, lung
cancer—there have been few new agents approved for bladder cancer within
the last 20 years, so there are low competitive barriers to entry for
bladder cancer compared with some other cancer markets.”
On Wednesday, February 29, 2012, Decision Resources will be hosting a
webinar for subscribers to the Bladder Cancer report that will
highlight novel agents for the treatment of metastatic bladder cancer
entitled Bladder Cancer: Novartis Poised to Dominate Market as
Targeted Agents Launch for Advanced Disease. Members of the
media interested in attending the webinar should contact Lisa Osgood at [email protected]
About Bladder Cancer
Bladder Cancer is offered as part of Decision Resources’ Niche
Markets and Rare Diseases service. Each report assesses the commercial
opportunity of a select drug market across the United States, France,
Germany, Italy, Spain and the United Kingdom. The report provides
detailed coverage of patient populations, current therapies, unmet needs
and emerging therapies, and includes a market forecast and primary
research with country-specific thought leaders.
About Decision Resources
Decision Resources (www.decisionresources.com)
is a world leader in market research publications, advisory services and
consulting designed to help clients shape strategy, allocate resources
and master their chosen markets. Decision Resources is a Decision
Resources Group company.
About Decision Resources Group
Decision Resources, Inc. is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and
data to make informed decisions. Please visit Decision Resources Group
All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.